CN102985100A - 用于治疗copd恶化的组合物和方法 - Google Patents

用于治疗copd恶化的组合物和方法 Download PDF

Info

Publication number
CN102985100A
CN102985100A CN201180019387XA CN201180019387A CN102985100A CN 102985100 A CN102985100 A CN 102985100A CN 201180019387X A CN201180019387X A CN 201180019387XA CN 201180019387 A CN201180019387 A CN 201180019387A CN 102985100 A CN102985100 A CN 102985100A
Authority
CN
China
Prior art keywords
antibody
copd
patient
certain embodiments
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180019387XA
Other languages
English (en)
Chinese (zh)
Inventor
D·芬奇
A·科伊尔
M·施藤普夫利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McMaster University
MedImmune Vaccines Inc
Original Assignee
McMaster University
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McMaster University, MedImmune Vaccines Inc filed Critical McMaster University
Publication of CN102985100A publication Critical patent/CN102985100A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180019387XA 2010-04-16 2011-04-18 用于治疗copd恶化的组合物和方法 Pending CN102985100A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US61/325,241 2010-04-16
US41610210P 2010-11-22 2010-11-22
US61/416,102 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (1)

Publication Number Publication Date
CN102985100A true CN102985100A (zh) 2013-03-20

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180019387XA Pending CN102985100A (zh) 2010-04-16 2011-04-18 用于治疗copd恶化的组合物和方法

Country Status (11)

Country Link
US (1) US20130149312A1 (enExample)
EP (1) EP2558112A4 (enExample)
JP (1) JP2013525310A (enExample)
KR (1) KR20130086141A (enExample)
CN (1) CN102985100A (enExample)
AU (1) AU2011239402A1 (enExample)
BR (1) BR112012026545A2 (enExample)
CA (1) CA2796083A1 (enExample)
MX (1) MX2012012063A (enExample)
RU (1) RU2012148721A (enExample)
WO (1) WO2011130745A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182121A1 (ja) * 2014-05-29 2015-12-03 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
WO2016168696A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Methods to improve induction of iga antibodies by vaccines
WO2016197087A1 (en) 2015-06-05 2016-12-08 The University Of Rochester Shape-memory polymers and methods of making and use thereof
KR102208549B1 (ko) * 2019-05-16 2021-01-27 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
EP4069847A4 (en) * 2019-12-02 2023-11-15 Onspira Therapeutics, Inc. Treatment of lower airways disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097712A1 (en) * 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
CN101133084A (zh) * 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
US20090022733A1 (en) * 2000-05-12 2009-01-22 Immunex Corporation Methods for treating Disease with an IL-1R antibody
CN102307901A (zh) * 2008-11-07 2012-01-04 米迪缪尼有限公司 抗il-1r1结合成员

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
KR20080077238A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090022733A1 (en) * 2000-05-12 2009-01-22 Immunex Corporation Methods for treating Disease with an IL-1R antibody
US20040097712A1 (en) * 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
CN101133084A (zh) * 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
CN102307901A (zh) * 2008-11-07 2012-01-04 米迪缪尼有限公司 抗il-1r1结合成员

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途

Also Published As

Publication number Publication date
RU2012148721A (ru) 2014-05-27
WO2011130745A1 (en) 2011-10-20
BR112012026545A2 (pt) 2019-09-24
CA2796083A1 (en) 2011-10-20
MX2012012063A (es) 2013-03-21
EP2558112A4 (en) 2014-06-18
KR20130086141A (ko) 2013-07-31
EP2558112A1 (en) 2013-02-20
JP2013525310A (ja) 2013-06-20
AU2011239402A1 (en) 2012-10-25
US20130149312A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
EP3703818B1 (en) Il-4r antagonist for use in a method for treating or preventing asthma
AU2018253118B2 (en) Treatment of asthma with anti-TSLP antibody
ES2701093T3 (es) Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
JP5137053B2 (ja) 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
JP2018158934A (ja) 抗ｉｌ−５抗体を投与するための方法
JP6458086B2 (ja) 変形性関節症の治療
CN102985100A (zh) 用于治疗copd恶化的组合物和方法
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
CN101022828B (zh) B因子、补体旁路的抑制及与此相关的方法
US20230174656A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
KR20240008231A (ko) 급성호흡곤란증후군의 치료 또는 예방 방법
US20240025991A1 (en) Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
WO2025095864A1 (en) Treatment
EP3957364A1 (en) A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
WO2013032943A1 (en) Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130320